Nueclear Web Banner
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Factors potentially associated with gemcitabine-based chemotherapy-induced thrombocytopenia in Chinese patients with nonsmall cell lung cancer


1 Department of Pharmacy; Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, People's Republic of China
2 Department of Pharmacy, Integrated Chinese and Western Medicine Hospital of Zhejiang Province, Hangzhou 310003, Zhejiang, People's Republic of China
3 Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology; Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, People's Republic of China
4 Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, People's Republic of China
5 Institute for Individualized Medicine, Hangzhou First People's Hospital, Hangzhou, Zhejiang 310006, People's Republic of China

Correspondence Address:
Neng-Ming Lin,
Institute for Individualized Medicine, Hangzhou First People's Hospital, Hangzhou, Zhejiang 310006
People's Republic of China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Objective: To investigate the prevalence and characteristics of gemcitabine-based chemotherapy-induced thrombocytopenia in Chinese patients with nonsmall cell lung cancer (NSCLC). Materials and Methods: Medical records of 197 patients with histologically proven NSCLC received gemcitabine-based chemotherapy from June 2011 to June 2013 in our hospital were collected. The relative risk factors were identified and evaluated by univariate and multivariate analyses. Results: The incidence of gemcitabine-based chemotherapy-induced thrombocytopenia in these NSCLC patients was 85.8%. Between thrombocytopenia and nonthrombocytopenia patients, in patients with thrombocytopenia and thrombocytopenia, we found Stage III/IV patients got more probabilities for thrombocytopenia (P < 0.01). In addition, patients who received gemcitabine and cisplatin (GP) regimen resulted in more thrombocytopenia than gemcitabine and carboplatin (GC) and other regimens (P < 0.001). In addition, majority of the thrombocytopenia patients presented thrombocytopenia in their first cycle (P < 0.001). Whereas, other potential risk factors such as age, gender, performance status value, diabetes mellitus or not, and other underlying disease (hypertension and hepatopathy) were not showed such significance in this study. Further, the multivariate analysis revealed that stage (odds ratio [OR] 7.113, P < 0.01) and chemotherapy cycles (OR 0.543, P < 0.01) were also statistically significant independent risk factors for gemcitabine-based chemotherapy-induced thrombocytopenia. Conclusion: This study shows that thrombocytopenia is common in Chinese NSCLC patients receiving gemcitabine-based regimens. Chemotherapy cycles and stage might be the important factors influencing the occurrence of gemcitabine-based regimens-induced thrombocytopenia.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Wang Z
    -  Cai XJ
    -  Chen LY
    -  Cheng B
    -  Shi L
    -  Lei L
    -  Ye LQ
    -  Lin NM
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed361    
    PDF Downloaded17    

Recommend this journal